Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors
Phase 1
45
about 18 years
18+
1 site in TX
About this study
Researchers are testing a new treatment called CAdVEC, which is an oncolytic adenovirus. The trial is also testing the safety and effectiveness of combining this treatment with HER2-specific autologous CAR T cells in people with advanced HER2-positive solid tumors.
Based on ClinicalTrials.gov records.
What participants do
- 1.Receive CAdVEC
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Primary: Number of patients with dose limiting toxicity (DLT) by CTCAE 5.0
Secondary: Disease Control Rate (DCR), Number of treatment related adverse events with grade 3 or greater severity by CTCAE 5.0, Overall Response Rate (ORR) according to RECIST1.1 criteria, Overall Survival (OS), Progression Free Survival (PFS)
Oncology